Digital biomanufacturing supporting vascularization in 3D bioprinting
Whitford W., Hoying JB.
Narrative Review, published in Int J Bioprint (2017) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Int J Bioprint (2017)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 33094177
- PMCID
- PMC7575623
- DOI
- 10.18063/ijb.2017.01.002
- Citations
- 3
Abstract (original English)
Synergies in bioprinting are appearing from individual researchers focusing on divergent aspects of the technology. Many are now evolving from simple mono-dimensional operations to model-controlled multi-material, interpenetrating networks using multi-modal deposition techniques. Bioinks are being designed to address numerous critical process parameters. Both the cellular constructs and architectural design for the necessary vascular component in digitally biomanufactured tissue constructs are being addressed. Advances are occurring from the topology of the circuits to the source of the of the biological microvessel components. Instruments monitoring and control of these activates are becoming interconnected. More and higher quality data are being collected and analysis is becoming richer. Information management and model generation is now describing a "process network." This is promising; more efficient use of both locally and imported raw data supporting accelerated strategic as well as tactical decision making. This allows real time optimization of the immediate bioprinting bioprocess based on such high value criteria as instantaneous progress assessment and comparison to previous activities. Finally, operations up- and down-stream of the deposition are being included in a supervisory enterprise control.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.